Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index
Introduction: Assessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation. The number of acute medication intakes per each monthly migraine day (MMD) could provide insights on migraine burden and represent a new proxy of treatment effectiveness in clinical trials and real-life studies. We evaluated … celý popis
Uloženo v:
Podrobná bibliografie
- Hlavní autor
- Další autoři
- , , , , , ,
- Typ dokumentu
- Články
- Publikováno v
- Frontiers in neurology. -- ISSN 1664-2295. -- Roč. 13, č. - (2022), s. 846717
- Témata
Instituce:
Bibliographia medica Čechoslovaca
MARC
| LEADER | 00000naa a2200000 a 4500 | ||
|---|---|---|---|
| 001 | bmc22009898 | ||
| 003 | CZ-PrNML | ||
| 005 | 20220425131620.0 | ||
| 007 | ta | ||
| 008 | 220420s2022 sz f 000 0|eng|| | ||
| 009 | AR | ||
| 024 | 7 | |a 10.3389/fneur.2022.846717 |2 doi | |
| 035 | |a (PubMed)35295829 | ||
| 040 | |a ABA008 |b cze |d ABA008 |e AACR2 | ||
| 041 | 0 | |a eng | |
| 044 | |a sz | ||
| 100 | 1 | |a Sette, Lucia |u Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy | |
| 245 | 1 | 0 | |a Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index / |c L. Sette, V. Caponnetto, R. Ornello, T. Nežádal, D. Čtrnáctá, J. Šípková, Z. Matoušová, S. Sacco |
| 520 | 9 | |a Introduction: Assessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation. The number of acute medication intakes per each monthly migraine day (MMD) could provide insights on migraine burden and represent a new proxy of treatment effectiveness in clinical trials and real-life studies. We evaluated the effect of monoclonal antibodies acting on calcitonin gene-related peptide (CGRP) pathway on the consumption of migraine acute medication in real-life. Methods: In two headache centers in Prague (CZ), we included and followed up to 6 months consecutive patients treated with MoAbs acting on CGRP (erenumab or fremanezumab). For each month of treatment, we reported monthly drug intake (MDI) in doses of any medication, migraine-specific (MS), and non-migraine-specific (non-MS) medications, and computed a ratio between MMDs and MDI, i.e., Migraine Medication Index (MMI) for MS and non-MS medications. Results: We included 90 patients (91.1% women) with a median age of 47 [interquartile range (IQR) 42-51] years; 81 (90.0%) treated with erenumab and 9 (10.0%) with fremanezumab. Median MMDs decreased from 11 (IQR 8-14) at baseline to 4 (IQR 2-5) at Month 3 (p < 0.001 vs. baseline) and 3 (IQR 2-6) at Month 6 (p < 0.001 vs. baseline). Median MDI decreased from 15 drug intakes (IQR 11-20) at baseline to four drug intakes (IQR 2-7) at Month 3 (p < 0.001) and four drug intakes (IQR 2-7) at Month 6 (p < 0.001).The corresponding MDIs for MS medications were 10 (IQR 6-14) at baseline, 3 (IQR 1-5, p < 0.001) at Month 3, and 2 (IQR 0-4, p < 0.001) at Month 6. Monthly drug intakes for non-MS medications were 4 (IQR 0-9) at baseline, 1 (IQR 0-3, p < 0.001) at Month 3 and at Month 6.Median MMI decreased from 1.32 (IQR 1.11-1.68) at baseline to 1.00 (IQR 1.00-1.50, p < 0.001) at Month 3 and 1.00 (IQR 1.00-1.34, p < 0.001) at Month 6. Conclusions: We confirmed that MoAbs acting on CGRP pathway decrease acute migraine medication consumption. We proposed a new index that can be easily applied in clinical practice to quantify migraine burden and its response to acute medication. Our index could help optimizing migraine acute treatment in clinical practice. | |
| 655 | 2 | |a časopisecké články |7 D016428 |2 czmesh | |
| 700 | 1 | |a Caponnetto, Valeria |u Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy | |
| 700 | 1 | |a Ornello, Raffaele |u Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy | |
| 700 | 1 | |a Nežádal, Tomáš |u Department of Neurology, 1st Faculty of Medicine, Military University Hospital Prague, Charles University, Prague, Czechia | |
| 700 | 1 | |a Čtrnáctá, Dana |u Department of Neurology, 1st Faculty of Medicine, Military University Hospital Prague, Charles University, Prague, Czechia | |
| 700 | 1 | |a Šípková, Jitka |u Department of Neurology, 1st Faculty of Medicine, Military University Hospital Prague, Charles University, Prague, Czechia | |
| 700 | 1 | |a Matoušová, Zuzana |u Department of Neurology, 2nd Faculty of Medicine, Motol University Hospital Prague, Charles University, Prague, Czechia | |
| 700 | 1 | |a Sacco, Simona |u Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy | |
| 773 | 0 | |w MED00174552 |t Frontiers in neurology |x 1664-2295 |g Roč. 13, č. - (2022), s. 846717 | |
| 856 | 4 | 1 | |u https://pubmed.ncbi.nlm.nih.gov/35295829 |y Pubmed |
| 910 | |a ABA008 |b sig |c sign |y - |z 0 | ||
| 999 | |a ind | ||
| BAS | |a 3 | ||
| BAS | |a PreBMC | ||
| BMC | |a 2022 |b 13 |c - |d 846717 |e 20220228 |i 1664-2295 |m Frontiers in neurology |n Front. neurol. |x MED00174552 | ||
| FF6 | |b a f 000 0| | ||
| LZP | |a Pubmed-20220420 | ||